NCT03576469 - A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 13, 2018

Primary Completion Date

December 1, 2019

Study Completion Date

March 1, 2020

Conditions

CVI - Common Variable Immunodeficiency

Interventions

BIOLOGICAL

C1-esterase inhibitor [recombinant] (C1-INH-R)

C1-INH-R is FDA approved and indicated for the treatment of acute attacks of angioedema in adolescent and adult patients with Hereditary Angioedema (HAE) as a replacement for low levels of C1-esterase inhibitor or low function of C1-esterase inhibitor

Trial Locations (1)

80112

IMMUNOe Research Centers, Centennial